Turkish Journal of Medical Sciences
Abstract
AbstractAim: Rheumatoid factor (RF) and Anti Citrullinated Peptide (anti-CCP) is specific for rheumatoid arthritis (RA) diagnosis. However they could be positive in other disease and even healthy populations. It was aimed to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.Material and Method: The National Electronic Health Database, which contains the clinical records of over eighty million people, is used to design this multi-center, retrospective cohort study. The subjects included in the study were divided into age groups in 10-year periods. RA cases were identified by using ICD-10 codes that included M05,M06, M08,and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and genderResults: During the 1.1.2018-31.12.2021 period, 13.918.072 RF tests were performed in 11.849.440 people, whereas 1.183.607 anti-CCP test were performed in 1.020.967 people. 797.089 people had at least once both tests performed. RF positivity rate in patients who only requested RF test was 14.72% and it was 35.04% for anti-CCP positivity in only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%.RA diagnosis is made in in 27.8% of RF-positive people, in 39.73% of anti-CCP-positive people and in %56.6 of co RF and anti CCP positive people. RF positivity and concomitant RF and anti-CCP positivity increased with the age and more common in females.Conclusion: RF and anti-CCP positivity could be seen in a healthy population with female predominance. As the age increases, the risk of RF positivity is increased, however anti –CCP positivity does not change. Concomitant RF and anti-CCP positivity has the highest risk of RA development with respect to either antibody positivity alone.
Author ORCID Identifier
HASAN SATIŞ: 0000-0002-7605-1301
ABDULSAMET ERDEN: 0000-0002-8084-2018
EMRE BİLGİN: 0000-0002-2260-4660
GİZEM AYAN: 0000-0003-1889-9619
BERKAN ARMAĞAN: 0000-0003-4409-059x
DUYGU TECER: 0000-0002-8816-6181
ALPER SARI: 0000-0002-3286-0940
UMUT KALYONCU: 0000-0001-7129-2109
MURAT ÇAĞLAYAN: 0000-0003-3486-6067
MUSTAFA', 'MUSTAFA MAHİR ÜLGÜ: 0000-0003-0825-1851
MUSTAFA', 'MUSTAFA OKAN AYVALI: 0000-0002-0116-5152
NAİM ATA: 0000-0001-6947-2821
NAİM', 'ŞUAYİP ATA', 'BİRİNCİ: 0000-0001-8104-6198
DOI
10.55730/1300-0144.5872
Keywords
anti citrullinated peptide, nationwide, Auto-antibody, rheumatoid arthritis, rheumatoid factor
First Page
949
Last Page
955
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
SATIŞ, H, ERDEN, A, BİLGİN, E, AYAN, G, ARMAĞAN, B, TECER, D, SARI, A, KALYONCU, U, ÇAĞLAYAN, M, ÜLGÜ, M. M, AYVALI, M. O, ATA, N, & BİRİNCİ, Ş (2024). A nationwide study: prevalence of rheumatoid factor and anti- citrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis. Turkish Journal of Medical Sciences 54 (5): 949-955. https://doi.org/10.55730/1300-0144.5872